within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EL01_Ibrutinib;

model Ibrutinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.034,
    Cl = 0.0002777777777777778,
    adminDuration = 600,
    adminMass = 560 / 1000000,
    adminCount = 1,
    Vd = 6.83,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01205,
    Tlag = 10.020000000000001,
    Vdp = 0.92,
    k12 = 0.0010527777777777777,
    k21 = 0.0010527777777777777);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ibrutinib</td></tr><tr><td>ATC code:</td><td>L01EL01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>560</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>6830</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1000</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ibrutinib is a small molecule Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia. It is an orally administered tyrosine kinase inhibitor, approved and used today for the treatment of select hematological cancers.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with B-cell malignancies, including both healthy and patient populations, most studies include both sexes aged 18 and older; values reflect typical exposure after oral administration at the recommended clinical dose.</p><h4>References</h4><ol><li><p>Al-Ghazawi, M, et al., &amp; Najib, N (2021). Population Pharmacokinetics of Ibrutinib in Healthy Adults. <i>European journal of drug metabolism and pharmacokinetics</i> 46(3) 405–413. DOI:<a href=\"https://doi.org/10.1007/s13318-021-00679-z\">10.1007/s13318-021-00679-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33740218/\">https://pubmed.ncbi.nlm.nih.gov/33740218</a></p></li><li><p>Eisenmann, ED, et al., &amp; Baker, SD (2021). Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. <i>Cancer research communications</i> 1(2) 79–89. DOI:<a href=\"https://doi.org/10.1158/2767-9764.crc-21-0076\">10.1158/2767-9764.crc-21-0076</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34950932/\">https://pubmed.ncbi.nlm.nih.gov/34950932</a></p></li><li><p>Marostica, E, et al., &amp; Poggesi, I (2015). Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. <i>Cancer chemotherapy and pharmacology</i> 75(1) 111–121. DOI:<a href=\"https://doi.org/10.1007/s00280-014-2617-3\">10.1007/s00280-014-2617-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25381051/\">https://pubmed.ncbi.nlm.nih.gov/25381051</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EL01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ibrutinib;
